QI
AXSM icon

QS Investors’s Axsome Therapeutics AXSM Stock Holding History

QS Investors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-3,100
Closed -$221K – 1188
2020
Q3 		$221K Sell
3,100
-13,300
-81% -$1.04M ﹤0.01% 1046
2020
Q2 		$1.35M Hold
16,400
– – 0.02% 635
2020
Q1 		$965K Buy
+16,400
New +$1.34M 0.02% 673

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

QS Investors's AXSM Position: Q4 2020 in Review

QS Investors sold out of Axsome Therapeutics (AXSM) in Q4 2020, closing a stake of 3,100 shares — an estimated $221K sold.

QS Investors first reported a position in AXSM in Q1 2020 and held it in 3 quarters. The position peaked at $1.35M in Q2 2020. 179 funds tracked by Wall St. Rank hold AXSM as of Q4 2020.

  • QS Investors reported no remaining Axsome Therapeutics position as of Q4 2020 after selling out during the quarter.
  • QS Investors sold 3,100 Axsome Therapeutics shares in Q4 2020, an estimated $221K.
  • QS Investors first reported a position in Axsome Therapeutics in Q1 2020 and held it in 3 quarters.
  • QS Investors's Axsome Therapeutics position peaked at $1.35M in Q2 2020.
  • 179 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2020.

Based on QS Investors's 13F filing for Q4 2020, filed 10 Feb 2021.